RAPP Rapport Therapeutics Inc.

Price (delayed)

$34.13

Market cap

$1.64B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.03

Enterprise value

$1.58B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 29
Highlights
Rapport Therapeutics's debt has decreased by 15% YoY and by 6% from the previous quarter
Rapport Therapeutics's equity has soared by 60% YoY but it has decreased by 10% from the previous quarter
The net income has plunged by 55% YoY and by 28% from the previous quarter
Rapport Therapeutics's EPS has decreased by 48% YoY and by 17% from the previous quarter

Key stats

What are the main financial stats of RAPP

RAPP stock price

How has the Rapport Therapeutics stock price performed over time
Intraday
-17.7%
1 week
-17.54%
1 month
-29.25%
1 year
28.07%
YTD
12.49%
QTD
-18.09%

Financial performance

How have Rapport Therapeutics's revenue and profit performed over time
Revenue
$20M
Gross profit
$20M
Operating income
-$153.52M
Net income
-$137.16M
Gross margin
100%
Net margin
-685.8%
The net income has plunged by 55% YoY and by 28% from the previous quarter
Rapport Therapeutics's operating income has shrunk by 51% YoY and by 26% QoQ
Rapport Therapeutics's net margin has decreased by 28% from the previous quarter
RAPP's operating margin is down by 26% since the previous quarter

Price vs fundamentals

How does RAPP's price correlate with its fundamentals

Growth

What is Rapport Therapeutics's growth rate over time

Valuation

What is Rapport Therapeutics stock price valuation
P/E
N/A
P/B
3.86
P/S
81.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
79.19
Rapport Therapeutics's EPS has decreased by 48% YoY and by 17% from the previous quarter
Rapport Therapeutics's equity has soared by 60% YoY but it has decreased by 10% from the previous quarter
RAPP's P/B is 47% higher than its last 4 quarters average of 3.2

Efficiency

How efficient is Rapport Therapeutics business performance
Rapport Therapeutics's ROS has decreased by 28% from the previous quarter
The ROA has decreased by 17% QoQ but it has increased by 4.2% YoY
Rapport Therapeutics's ROE has decreased by 17% from the previous quarter but it has increased by 3.3% YoY
The company's return on invested capital fell by 15% QoQ and by 2.9% YoY

Dividends

What is RAPP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RAPP.

Financial health

How did Rapport Therapeutics financials performed over time
RAPP's total liabilities has surged by 64% year-on-year and by 38% since the previous quarter
The total assets has surged by 61% year-on-year but it has declined by 8% since the previous quarter
Rapport Therapeutics's debt is 98% less than its equity
Rapport Therapeutics's debt to equity has shrunk by 60% YoY
Rapport Therapeutics's equity has soared by 60% YoY but it has decreased by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.